Prostate cancer accounts for 25% of male cancers. If it is rare before the age of 50, its incidence increases gradually over the years. Since the 1990s, mortality has been falling thanks to improved treatments and early detection. Indeed, as recalled by the National Cancer Institute, 80% of cancers are diagnosed while they are still located in the prostate.
A recent discovery could further improve patient survival. In the UK, researchers from the University of East Anglia have helped develop a new blood test (
Prostate Screening
EpiSwitch –
PSE) capable of detecting prostate cancer with greater efficiency than current methods. This test has an accuracy of 94%, which is better than the prostate-specific antigen (PSA) assay currently used.
Cancer: “France must arm itself with sovereign technologies”
“There is currently no single test for prostate cancer, but PSA blood tests are among the most used, alongside physical exams, MRIs and biopsies. However, PSA blood tests are not routinely used to screen for prostate cancer, as the results may not be reliable,” says Professor Dmitry Pshezhetskiy, from UEA’s Norwich Medical School. Before completing: